Status:
COMPLETED
Observational Study of Heart Valve Disease in Patients With Parkinson's Disease Treated With Pergolide
Lead Sponsor:
Société Française de Cardiologie
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Parkinson's Disease
Pergolide
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to determine whether patients with Parkinson's disease and treated with pergolide have a higher risk of heart valve disease compared to patients with Parkinson's disease n...
Detailed Description
Pergolide is an ergot dopamine receptor agonist with demonstrated efficacy in Parkinson's disease. Last year, two studies showed that pergolide can induce unexpected heart valve disease potentially se...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease
- Hoehn and Yahr score inferior or equal to 4
- treated with pergolide since more than 3 months (pergolide group)
- never treated by pergolide (control group)
Exclusion
- Parkinson + syndrome, multiple system atrophy, supranuclear palsy
- hoehn and yahr score equal to 5
Key Trial Info
Start Date :
April 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2007
Estimated Enrollment :
149 Patients enrolled
Trial Details
Trial ID
NCT00202657
Start Date
April 1 2005
End Date
February 1 2007
Last Update
December 6 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Investigation Centre, Pitie-Salpetriere Hospital
Paris, France, 75013